Piascledine 300 Capsules 300mg N30
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Neomyrami compounds of avocado and soybean oils
Release form
Capsules
Composition
1 g contains natamycin 10 mg, neomycin (in the form of neomycin sulfate) 3500 U, hydrocortisone micronized 10 mg, excipients: sodium citrate - 14 mg; emulsifier F - 115 mg; sorbitan stearate - 30 mg; cetylether wax - 60 mg; cetiol V 150; macrogol stearate 100-20 mg; methyl parahydroxybenzoate - 2 mg; propyl parahydroxybenzoate - 0.5 mg; purified water - up to 1000 mg
Pharmacological effect
Corrective metabolism of cartilage tissue. The drug of plant origin, regulating metabolic processes in cartilage tissue. It has a symptomatic anti-inflammatory and analgesic effect on the joints. It helps to slow down the development of the degenerative process in the cartilage tissue of the joints, reduces joint pain associated with this process, restores the patient's motor function. In experimental studies, it was proved that the drug has a regenerating effect on cartilage, stimulating the synthesis of collagen in articular chondrocytes. The action of unsaponable soybean oil and avocado oil compounds increases collagen production and inhibit the stimulating effect of interleukin-1 (IL-1) on collagenase synthesis. Neomyrany soybean oil and avocado oil compounds: - increase the production of plasminogen activator inhibitor, thereby reducing cartilage damage, both indirectly through the stimulation of metalloproteinases, and by direct effects on cartilage, activating the degradation of proteoglycans, which prevents the destruction of cartilage; - increase the effect of transforming growth factor β1 (TGF) in chondrocytes, which has a powerful anabolic property; - regulate the synthesis of macromolecules of the intercellular substance of articular cartilage, are a powerful stimulator of the synthesis of macromolecules of hyaline cartilage, as well as periodontal tissue, preventing tooth loss
Pharmacokinetics
Data on the pharmacokinetics of the drug Piascledine 300 not provided
Indications
Combined therapy of osteoarthritis of the knee and hip joints of the I-III stage; adjuvant periodontitis therapy
Contraindications
Age up to 18 years; - pregnancy; - lactation period (breastfeeding); - hypersensitivity to the drug components
Use during pregnancy and lactation
The drug is not recommended for use during pregnancy and lactation (breastfeeding).
Dosage and administration
The drug is administered orally in 1 caps / day, preferably in the morning with meals, with 250 ml of water. The course of treatment is 6 months. Increasing the duration and conducting repeated courses of treatment is possible after consulting a doctor.
Side effects
Allergic reactions are possible. It is rarely possible to increase the following laboratory parameters: the activity of hepatic transaminases, alkaline phosphatase, GGT and bilirubin level
Overdose
To date, no cases of overdose of Piascledine 300 have been reported.
Interaction with other drugs
Interaction with other drugs is not described.
special instructions
At the initial stage of treatment, Piaskledina 300 can be combined with NSAIDs and / or analgesics. Influence on ability to drive motor transport and control mechanisms Does not affect the activity requiring high concentration of attention and speed of psychomotor reactions